Multi-ancestry genetic study in 5,876 patients identifies an association between excitotoxic genes and early outcomes after acute ischemic stroke - Ibanez, Laura; Heitsch, Laura; Carrera, Caty; Farias, Fabiana H.G.; Dhar, Rajat; Budde, John; Bergmann, Kristy; Bradley, Joseph; Harari, Oscar; Phuah, Chia-Ling; Lemmens, Robin; Oliveira Souza, Alessandro A. Viana; et al. (medRxiv, 2020)
During the first hours after stroke onset neurological deficits can be highly unstable: some patients rapidly improve, while others deteriorate. This early neurological instability has a major impact on long-term outcome. Here, we aimed to determine the genetic architecture of early neurological instability measured by the difference between NIH stroke scale (NIHSS) within six hours of stroke onset and NIHSS at 24h (ΔNIHSS). A total of 5,876 individuals from seven countries (Spain, Finland, Poland, United States, Costa Rica, Mexico and Korea) were studied using a multi-ancestry meta-analyses. We found that 8.7% of ΔNIHSS variance was explained by common genetic variations, and also that early neurological instability has a different genetic architecture than that of stroke risk. Seven loci (2p25.1, 2q31.2, 2q33.3, 4q34.3, 5q33.2, 6q26 and 7p21.1) were genome-wide significant and explained 2.1% of the variability suggesting that additional variants influence early change in neurological deficits. We used functional genomics and bioinformatic annotation to identify the genes driving the association from each loci. eQTL mapping and SMR indicate that ADAM23 (log Bayes Factor (LBF)=6.34) was driving the association for 2q33.3. Gene based analyses suggested that GRIA1 (LBF=5.26), which is predominantly expressed in brain, is the gene driving the association for the 5q33.2 locus. These analyses also nominated PARK2 (LBF=5.30) and ABCB5 (LBF=5.70) for the 6q26 and 7p21.1 loci. Human brain single nuclei RNA-seq indicates that the gene expression of ADAM23 and GRIA1 is enriched in neurons. ADAM23, a pre-synaptic protein, and GRIA1, a protein subunit of the AMPA receptor, are part of a synaptic protein complex that modulates neuronal excitability. These data provides the first evidence in humans that excitotoxicity may contribute to early neurological instability after acute ischemic stroke.Evidence before this study No previous genome-wide association studies have investigated the genetic architecture of early outcomes after ischemic stroke.Added Value of this study This is the first study that investigated genetic influences on early outcomes after ischemic stroke using a genome-wide approach, revealing seven genome-wide significant loci. A unique aspect of this genetic study is the inclusion of all of the major ethnicities by recruiting from participants throughout the world. Most genetic studies to date have been limited to populations of European ancestry.Implications of all available evidence The findings provide the first evidence that genes implicating excitotoxicity contribute to human acute ischemic stroke, and demonstrates proof of principle that GWAS of acute ischemic stroke patients can reveal mechanisms involved in ischemic brain injury.Competing Interest StatementCC receives research support from: Biogen, EISAI, Alector and Parabon, and is a member of the advisory board of ADx Healthcare and Vivid Genomics. JML receives research support from Biogen, and is a consultant for Regenera. EAT and LCB are employed by Biogen. JFA has received speaker or consultant honoraria from Bayer, Boehringer Ingelheim, Pfizer-BMS, Daiichi Sankyo, Amgen and Medtronic. TT receives or has received research support from Bayer, Boehringer Ingelheim and Bristol Myers Squibb; he is a member of advisory boards for Bayer, Boehringer Ingelheim, Bristol Myers Squibb and Portola Pharmaceuticals; and he is granted international patents: new therapeutic uses (method to prevent brain edema and reperfusion injury), and thrombolytic compositions (method to prevent post-thrombolytic hemorrhage formation). The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publicationFunding StatementEmergency Medicine Foundation Career Development Grant; AHA Mentored Clinical & Population Research Award (14CRP18860027); NIH/NINDS-R01-NS085419 (CC, JML); NIH/NINDS-R37-NS107230, NIH/NINDS U24-NS107230 (JML); NIH/NINDS-K23-NS099487 (LH); Barnes-Jewish Hospital Foundation (JML); Biogen (CC, JML); Helsinki University Central Hospital; Finnish Medical Foundation; Finland government subsidiary funds; Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (grants Registro BASICMAR Funding for Research in Health (PI051737), GWALA project from Fondos de Investigacion Sanitaria ISC III (PI10/02064, PI12/01238 and PI15/00451), JR18/00004); Fondos FEDER/EDRF Red de Investigacion Cardiovascular (RD12/0042/0020); Fundacio la Marato TV3; Genestroke Consortium (76/C/2011); Recercaixa13 (JJ086116). Tomas Sobrino (CPII17/00027), Francisco Campos (CPII19/00020) and Israel Fernandez are supported by Miguel Servet II Program from Instituto de Salud Carlos III and Fondos FEDER. Israel Fernandez is also supported by Maestro project (PI18/01338) and Pre-test project (PMP15/00022) from Instituto de Salud Carlos III and Fondos Feder, Agaur; and Epigenesis project from Marato TV3 Foundation. Jose Castillo, Joan Montaner, Antonio Davalos, Joan Marti-Fabregas, Juan Arenillas and Israel Fernandez,are supported by Invictus plus Network (RD16/0019) from Instituto de Salud Carlos III and Fondos Feder. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-2013/07559-3) (ILC), Sigrid Juselius Foundation. Sigrid Juselius Foundation. The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html.Boryana Stamova, Bradley Ander and Frank Sharp are supported by NIH awards: NS097000, NS101718, NS075035, NS079153 and NS106950.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards at every participating site. Written informed consent was obtained from all participants or their family members. All research was performed according to the approved protocols and consents All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics of the GENISIS dataset used for these analyses are available upon request. Individual data for the full GENISIS dataset will be uploaded to dbGAP titled: Genetics of Early Neurological Instability After Ischemic Stroke (GENISIS).